Study: Many with early stages of breast cancer don’t need chemotherapy
Video taken from the channel: LOCAL 12
Oncotype DX testing to determine if a breast cancer patient will benefit from chemotherapy
Video taken from the channel: VJOncology
Women with the most common kind of breast cancer can skip chemotherapy: Study
Video taken from the channel: Good Morning America
Study: Some breast cancer patients may not need chemo
Video taken from the channel: KARE 11
Testing Allows Cancer Patients to Skip Chemo
Video taken from the channel: Associated Press
Most breast cancer patients could avoid chemo with use of genetic testing
Video taken from the channel: ecancer
Gene test finds which breast cancer patients can skip chemo
Video taken from the channel: LOCAL 12
“Basically, it’s going to spare a lot of unnecessary chemotherapy in patients with breast cancer.” The genomic test for this type of breast cancer, called Oncotype DX, measures the expression of 21. Many women with early breast cancer may not need chemo, study finds Genetic test can help determine treatment for patients with smaller tumors that have not spread to the lymph nodes The new study. Personalising treatment Most progress towards personalising treatment has been in developing genetic tests for breast cancer, performed on tumour samples taken during surgery. One.
Current National Comprehensive Cancer Network (NCCN) guidelines on who should have genetic testing after a breast cancer diagnosis miss about half of people with a genetic mutation linked to the disease, according to a study. The research was published online on Dec. 7, 2018, by the Journal of Clinical Oncology. Some women inherit changes (mutations) in certain genes that increases their risk of breast cancer (and possibly other cancers).
Genetic testing can be done to look for mutations in some of these genes. While testing can be helpful in some cases, not every woman needs to be tested, and the pros and cons need to be considered carefully. Genetic testing is available for hereditary breast and ovarian cancer. Most breast and ovarian cancer is not caused by inherited mutations, so genetic testing will not help most women with a family health history of breast and ovarian cancer.
Genetic testing will not identify the cause for some hereditary breast and ovarian cancers, because the genes affected in these cancers are not yet known. Researchers say a new genetic test for breast cancer patients may indicate whether standard chemotherapy treatments will work. Their study, published in. “Only about 5 to 10% of cancer cases are related to genetics,” says Karen Lu, M.D., co-medical director of the Clinical Cancer Genetics Program at MD Anderson. “Genetic testing is a powerful tool to identify those individuals who are at especially increased risk for. A woman’s lifetime risk of developing breast and/or ovarian cancer is greatly increased if she inherits a harmful mutation in BRCA1 or BRCA2..
Breast cancer: About 12% of women in the general population will develop breast cancer sometime during their lives ().By contrast, a recent large study estimated that about 72% of women who inherit a harmful BRCA1 mutation and about 69% of women who. A genetic test called MammaPrint determined that nearly half the women slated for chemotherapy based on standard clinical assessments didn’t really need to undergo the challenging treatment.
List of related literature:
|from Introduction to Genomics|
|from Journal of the National Cancer Institute: JNCI.|
|from Health & Wellness|
|from Goldman’s Cecil Medicine,Expert Consult Premium Edition Enhanced Online Features and Print, Single Volume,24: Goldman’s Cecil Medicine|
|from Encyclopedia of Family Health|
|from The Cambridge Textbook of Bioethics|
|from The Breast E-Book: Comprehensive Management of Benign and Malignant Diseases|
|from Fatal Invention: How Science, Politics, and Big Business Re-create Race in the Twenty-First Century|
|from Practical Decision Making in Health Care Ethics: Cases and Concepts, Third Edition|
|from Genetics For Dummies|